share_log

Positive Earnings Growth Hasn't Been Enough to Get Dirui IndustrialLtd (SZSE:300396) Shareholders a Favorable Return Over the Last Year

Positive Earnings Growth Hasn't Been Enough to Get Dirui IndustrialLtd (SZSE:300396) Shareholders a Favorable Return Over the Last Year

正向的盈利增長並不足以讓迪瑞工業股份有限公司(SZSE:300396)股東在過去一年中獲得良好的回報。
Simply Wall St ·  08/06 19:51

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. That downside risk was realized by Dirui Industrial Co.,Ltd. (SZSE:300396) shareholders over the last year, as the share price declined 29%. That contrasts poorly with the market decline of 20%. At least the damage isn't so bad if you look at the last three years, since the stock is down 11% in that time. In the last ninety days we've seen the share price slide 35%.

passive investing在指數基金中是一個很好的辦法,可以確保你的回報大約與整個市場相匹配。當你購買個別股票時,你可以賺取更高的利潤,但也面臨着低於市場表現的風險。在過去一年中,迪瑞醫療股份有限公司的股東們經歷了這種下行風險,因爲股價下降了29%。與市場下降20%相比,這種對比非常糟糕。至少在看過去三年的表現後,損失還算不那麼嚴重,因爲在這段時間內股票下跌了11%。在過去的90天中,我們看到股價下跌了35%。

On a more encouraging note the company has added CN¥374m to its market cap in just the last 7 days, so let's see if we can determine what's driven the one-year loss for shareholders.

更令人鼓舞的是,迪瑞醫療股份有限公司在過去7天中已經爲市值增加了人民幣37400萬元,所以讓我們看看是什麼推動了股東們的一年虧損。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

不可否認的是,市場有時是高效的,但價格並不總是反映潛在的商業表現。一個不完美但簡單的方法來考慮公司市場感知如何改變是比較每股收益(EPS)變化和股價變動。

Even though the Dirui IndustrialLtd share price is down over the year, its EPS actually improved. Of course, the situation might betray previous over-optimism about growth.

儘管迪瑞醫療股份有限公司的股價一年來下跌了,但它的每股收益實際上有所提高。當然,這種情況可能背叛了對增長過度樂觀的先前預測。

It's surprising to see the share price fall so much, despite the improved EPS. So it's easy to justify a look at some other metrics.

儘管EPS有所改善,股價下跌了這麼多令人驚訝。因此,可以輕易地理解對其他一些指標進行研究的理由。

Dirui IndustrialLtd's revenue is actually up 29% over the last year. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

迪瑞醫療股份有限公司的營業收入實際上在過去一年中增長了29%。由於基本指標不容易解釋股價下跌,所以如果市場反應過度,就可能存在機會。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。

big
SZSE:300396 Earnings and Revenue Growth August 6th 2024
SZSE:300396 2024年8月6日的營收和收益增長

We know that Dirui IndustrialLtd has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on Dirui IndustrialLtd

我們知道迪瑞醫療股份有限公司的底線近年來有所提高,但未來會有什麼展望?這份免費的報告展示分析師的預測,應該有助於你對迪瑞醫療股份有限公司形成看法。

A Different Perspective

不同的觀點

While the broader market lost about 20% in the twelve months, Dirui IndustrialLtd shareholders did even worse, losing 27% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Dirui IndustrialLtd you should know about.

儘管廣義市場在12個月中損失了約20%,但迪瑞醫療股份有限公司的股東們的虧損更大,下降了27%(即使包括分紅)。然而,可能只是股價受到廣義市場的恐慌影響。如果有好的機會,監視基本面可能很值得。長期的投資者不會那麼沮喪,因爲他們每年可以獲得3%的回報,長達五年。最近的拋售可能是一個機會,所以檢查基本數據是否表明長期增長趨勢可能是值得的。雖然考慮市場條件可能對股價產生的不同影響非常重要,但還有其他更重要的因素。考慮風險,比如。每家公司都有它們自己的風險,我們已經發現了你應該知道的1個迪瑞醫療股份有限公司的警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論